Simplify Asset Management Inc. grew its stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 19.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 23,839 shares of the biotechnology company’s stock after buying an additional 3,919 shares during the quarter. United Therapeutics accounts for 0.2% of Simplify Asset Management Inc.’s holdings, making the stock its 21st biggest position. Simplify Asset Management Inc.’s holdings in United Therapeutics were worth $11,616,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Torren Management LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Raymond James Financial assumed coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. HC Wainwright increased their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.
Insider Activity
In other United Therapeutics news, Director Nilda Mesa sold 258 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total transaction of $150,137.94. Following the sale, the director directly owned 5,028 shares of the company’s stock, valued at approximately $2,925,944.04. This represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,648,140.36. The trade was a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 555,473 shares of company stock valued at $310,786,074. 8.60% of the stock is owned by insiders.
United Therapeutics Stock Performance
NASDAQ UTHR opened at $568.43 on Monday. The firm’s fifty day moving average price is $563.25 and its two-hundred day moving average price is $512.08. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm has a market capitalization of $24.13 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the company posted $6.63 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
